SK life science, a U.S. subsidiary of SK Biopharmaceuticals, is committed to accelerating the development of innovative treatments for central nervous system (CNS) disorders. Both companies are a part of something bigger — SK Group, one of the largest conglomerates in Korea and a global leader in energy, chemical, semiconductor and telecommunications industries. SK life science is headquartered in Paramus, New Jersey. SK life science and SK Biopharmaceuticals have eight compounds in development globally for the treatment of CNS disorders including epilepsy, attention-deficit hyperactivity disorder, schizophrenia and bipolar disorder, among others. For more information, please visit https://www.sklifescienceinc.com/innovation/#/pipeline. View our community guidelines here: https://bit.ly/2DmymLp